Gilead Sciences Inc
(GILD)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2009 | 03-2009 | 12-2008 | 09-2008 | 06-2008 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,040,874 | 1,663,646 | 1,459,302 | 1,209,424 | 1,119,599 |
| Marketable Securities | 203,394 | 396,648 | 330,760 | 709,870 | 228,122 |
| Receivables | 1,242,899 | 1,068,000 | 1,023,397 | 1,047,205 | 1,021,369 |
| Inventories | 969,971 | 936,727 | 927,868 | 897,623 | 856,287 |
| Income taxes - deferred | 185,439 | 135,612 | 140,882 | 100,772 | 133,482 |
| Other current assets | 78,127 | 164,929 | 126,066 | 140,791 | 115,194 |
| TOTAL | $4,001,307 | $4,615,915 | $4,278,408 | $4,326,683 | $3,669,377 |
| Non-Current Assets | |||||
| PPE Net | 697,426 | 679,437 | 528,799 | 512,281 | 493,012 |
| Investments And Advances | 1,654,178 | 1,548,595 | 1,449,577 | 1,336,968 | 1,560,631 |
| Intangibles | 1,570,790 | 0 | 123,008 | 0 | 0 |
| Other Non-Current Assets | 463,391 | 675,967 | 557,039 | 798,196 | 794,397 |
| TOTAL | $4,385,785 | $2,903,999 | $2,658,423 | $2,647,445 | $2,848,040 |
| Total Assets | $8,387,092 | $7,519,914 | $6,936,831 | $6,974,128 | $6,517,417 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 405,622 | 5,613 | 5,631 | 6,055 | 3,662 |
| Accounts payable and accrued liabilities | 649,999 | 578,362 | 601,200 | 631,525 | 606,245 |
| Accrued Expenses | 311,211 | 277,500 | 280,779 | 255,232 | 211,807 |
| TOTAL | $1,777,882 | $1,261,797 | $1,220,992 | $1,259,134 | $2,451,334 |
| Non-Current Liabilities | |||||
| Long Term Debt | 50,084 | 21,095 | 21,462 | 21,367 | 26,453 |
| Deferred Revenues | 46,345 | 48,300 | 42,963 | 40,205 | 38,764 |
| Other Non-Current Liabilities | 1,193,993 | 1,170,990 | 1,156,982 | 1,473,724 | 211,341 |
| TOTAL | $1,295,241 | $1,240,834 | $1,250,256 | $1,549,084 | $293,858 |
| Total Liabilities | $3,073,123 | $2,502,631 | $2,471,248 | $2,808,218 | $2,745,192 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,808,523 | 1,812,791 | 1,821,909 | 1,821,020 | 1,839,830 |
| Common Shares | 905 | 906 | 910 | 921 | 923 |
| Retained earnings | 1,019,839 | 672,956 | 300,314 | 531,001 | 265,435 |
| Other shareholders' equity | 147,411 | 324,838 | 234,250 | 17,190 | -11 |
| TOTAL | $5,313,969 | $5,017,283 | $4,465,583 | $4,165,910 | $3,772,225 |
| Total Liabilities And Equity | $8,387,092 | $7,519,914 | $6,936,831 | $6,974,128 | $6,517,417 |